Epithelial growth factor receptor inhibition against neuropathic pain
- Prosjektnummer
- 2016130
- Ansvarlig person
- Christian Kersten
- Institusjon
- Sørlandet sykehus HF
- Prosjektkategori
- Forskerstipend
- Helsekategori
- Neurological
- Forskningsaktivitet
- 2. Aetiology, 5. Treatment Developement
NEI
NEI
Nei
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Neurobiol Dis 2020 08;142():104961. Epub 2020 jun 10
PMID: 32531343
Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial.
Pain Med 2019 Dec 01;20(12):2495-2505.
PMID: 31106835
Oxaliplatin Plus Cetuximab: Are Uncertainties Unequivocally Settled?
J Clin Oncol 2019 Jun 20;37(18):1590-1591. Epub 2019 mai 2
PMID: 31046553
Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain.
Under Review
3. SFK4: Systematic registration of sensory neuropathy during treatment of cancer patients with inhibitors of the family of HER receptors: An exploratory observational feasibility study.
Under Review.
- Christian Kersten Forskningsgruppeleder
- Marte Grønlie Cameron Postdoktorstipendiat (annen finansiering)
- Svein Mjåland Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport